Patents Examined by Zinna Northington Davis
  • Patent number: 11912663
    Abstract: Disclosed are compounds of Formula IIIb, their stereoisomers, tautomers, deuterates, pharmacologically acceptable salts, or hydrates thereof, methods of their preparation and pharmaceutical compositions and uses comprising such compounds. The Formula IIIb compounds are useful and highly effective as multi-targeted tyrosine kinase inhibitors in treating several kinds of cancers such as pancreatic cancer, lung cancer, renal cancer, liver cancer, gastric cancer, cervical cancer, leukemia, prostatic cancer, and other antitumor uses.
    Type: Grant
    Filed: August 12, 2022
    Date of Patent: February 27, 2024
    Assignee: Shanghai AB PharmaTech Ltd.
    Inventor: Zheng-Yun James Zhan
  • Patent number: 11912720
    Abstract: Provided herein are rigid macrocycles comprising a poly(peri-naphthalene) diimide (PPNDI) submit and a second diimide subunit having both high photoluminescent and electron accumulation activities. Also provided herein are methods of preparation of the rigid macrocycles and methods of using the same.
    Type: Grant
    Filed: January 21, 2019
    Date of Patent: February 27, 2024
    Assignees: Northwestern University, King Abdulaziz City for Science and Technology (KACST)
    Inventors: Siva Krishna Mohan Nalluri, James Fraser Stoddart
  • Patent number: 11890281
    Abstract: The disclosure is in part directed to crystalline forms of (R)-1?-(3-(3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3H-spiro[benzofuran-2,4?-piperidin]-3-amine, its salt, and variants thereof.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: February 6, 2024
    Assignee: Relay Therapeutics, Inc.
    Inventors: Alexander M. Taylor, André Lescarbeau, Jing Wang, Yanyan Zhang, Gaodeng Lian
  • Patent number: 11884680
    Abstract: The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.
    Type: Grant
    Filed: December 31, 2020
    Date of Patent: January 30, 2024
    Assignee: Celgene Quanticel Research, Inc.
    Inventor: Amogh Boloor
  • Patent number: 11883391
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: January 30, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: James Campbell, Israel Charo, Thomas Schall, Rajinder Singh, Yibin Zeng, Penglie Zhang
  • Patent number: 11872222
    Abstract: This invention relates to the new use of neurokinin-1 receptor antagonists as a treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs. Specifically, when the mechanical injury to the lungs is induced by mechanical ventilation or by the act of coughing in a subset of patients with pulmonary fibrosis conditions who cough. The invention further relates to pharmaceutical compositions comprising neurokinin-1 receptor antagonist drugs and to combinations for such uses.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: January 16, 2024
    Assignee: NeRRe Therapeutics Limited
    Inventors: Mike Trower, Stephen Pawsey, Mary Kerr
  • Patent number: 11873288
    Abstract: The present invention provides compounds that are dual inhibitors of soluble epoxide hydrolase and fatty acid amide hydrolase. The present invention also provides methods of using the compounds to inhibit soluble epoxide hydrolase and fatty acid amide hydrolase, and to treat cancer.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: January 16, 2024
    Assignee: The Regents of the University of California
    Inventors: Bruce Hammock, Sean Kodani
  • Patent number: 11844787
    Abstract: This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.
    Type: Grant
    Filed: June 18, 2021
    Date of Patent: December 19, 2023
    Assignee: NOVO NORDISK HEALTH CARE AG
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, Jr., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang
  • Patent number: 11845738
    Abstract: The present invention provides: a methyl 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylate 1/2 ethane-1,2-disulfonic acid which is represented by formula (1) and is excellent in crystallinity; and a method for producing the same; and a production intermediate thereof; and a production method using this compound.
    Type: Grant
    Filed: June 3, 2021
    Date of Patent: December 19, 2023
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Joji Tsurumoto, Kenji Morokuma
  • Patent number: 11840514
    Abstract: Disclosed are complexes and methods of using the complexes as catalysts for addition of amines to unsaturated electrophiles, as well as novel compounds produced by the disclosed complexes and methods. The disclosed methods may utilize the disclosed complexes as catalysts for adding unprotected primary amines and secondary amines to unsaturated electrophiles in an enantioselective manner to produce novel compounds which may include amino substituted succinimide compounds.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: December 12, 2023
    Assignee: Northwestern University
    Inventors: Karl A. Scheidt, Brice Uno
  • Patent number: 11833144
    Abstract: A method for treating a mammal having an autoimmune disease, wherein said method comprises administering a SCD1 polypeptide inhibitor to said mammal, wherein said SCD1 polypeptide inhibitor is a compound having Formula (II): or a pharmaceutically acceptable salt thereof; wherein: R1 is halo; X is —(C?O)NR4—; Y is ?and R2, R3, and R4 are each independently H or an unsubstituted alkyl.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: December 5, 2023
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: John A. Copland, III, Hu Zeng
  • Patent number: 11820773
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: November 21, 2023
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Sandrine Vendeville, Yannick Debing, Pierre Jean-Marie Bernard Raboisson
  • Patent number: 11806346
    Abstract: Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: November 7, 2023
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Elizabeth M. Doherty, Longbin Liu, Matthew Lee, Mark Stuart Chambers, Karine Fabienne Malagu, Perla Breccia, Alan F. Haughan, Huw D. Vater, Andrew J. Stott, William R. K. Esmieu, Stephen John Webster, Amanda J. Van De Poël
  • Patent number: 11806386
    Abstract: The present invention relates to novel methods and therapies for treating, preventing or delaying the onset of type 1 diabetes. In one aspect, the invention provides a method of preventing, delaying the onset of, or delaying the progression of, type 1 diabetes (T1D) in an individual, the method comprising providing in the individual an anti-inflammatory compound; and a pancreatic autoantigen or a derivative or variant thereof; thereby preventing, delaying the onset of, or delaying the progression of, T1D in the individual.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: November 7, 2023
    Assignee: St. Vincent's Institute of Medical Research
    Inventors: Helen E. Thomas, Thomas W. H. Kay, Balasubramanian Krishnamurthy, Gaurang Jhala
  • Patent number: 11807626
    Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R1, R2, R3, A, E, L, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: November 7, 2023
    Assignee: Opna Bio SA
    Inventors: Songyuan Shi, John Buell, Zuojun Guo, Cuong Ly, Wayne Spevak, Mark Vander Wal, Jack Walleshauser, Chao Zhang, Jiazhong Zhang
  • Patent number: 11801243
    Abstract: Methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain are disclosed. In some methods, the AR-positive forms of cancer may be breast cancer, including triple negative forms, hormone receptor positive forms, and HER2-positive forms. In other methods, the AR-positive forms of cancer may be prostate cancer, including metastatic castration resistant prostate cancer. In some embodiments, methods of treating prostate cancer comprise the step of administering to a patient in need thereof the compound (1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 23, 2021
    Date of Patent: October 31, 2023
    Assignee: Forma Therapeutics, Inc.
    Inventors: Sylvie Guichard, Maureen Caligiuri, Anna Ericsson, Qunli Xu, Hesham Mohamed
  • Patent number: 11795163
    Abstract: The present invention relates to a novel compounds for inhibiting nicotinamide phosphoribosyltransferase (NamPT), a composition comprising the same, and various uses thereof.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: October 24, 2023
    Inventors: Hyun Seok Kim, Gyoon Hee Han
  • Patent number: 11793821
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: October 24, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Brendan M. Crowley, Ian M. Bell, Andrew John Harvey
  • Patent number: 11779578
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: October 10, 2023
    Assignee: Kymera Therapeutics, Inc.
    Inventor: Matthew M. Weiss
  • Patent number: 11771694
    Abstract: The present disclosure provides methods for treating or preventing a viral infection with one or more arylamide compounds, or pharmaceutically acceptable salts thereof, or compositions comprising the same, and pharmaceutical compositions comprising one or more arylamide compounds and at least one antiviral agent.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: October 3, 2023
    Assignee: Innovation Pharmaceuticals Inc.
    Inventors: Jane A. Harness, Leo Ehrlich, Warren Kyle Weston